(Q56986793)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21109771%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

title

Synergistic induction of PI-PLCβ1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21109771%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21109771%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

author name string

M Y Follo

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21109771%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

C Finelli

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21109771%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

S Mongiorgi

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21109771%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

C Clissa

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21109771%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

F Chiarini

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21109771%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

S Paolini

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21109771%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

G Martinelli

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21109771%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

A M Martelli

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21109771%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

L Cocco

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21109771%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

language of work or name

English

0 references

publication date

26 November 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21109771%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21109771%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

volume

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21109771%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21109771%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

page(s)

271-280

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21109771%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/leu.2010.266

17 January 2020

exact match

0 references

cites work

Epigenetic tools in potential anticancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.266

Epigenetic changes in the myelodysplastic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.266

Effects of 5-aza-2'-deoxycytidine on proliferation, differentiation and p15/INK4b regulation of human hematopoietic progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.266

Reversal of p15/INK4b hypermethylation in AML1/ETO-positive and -negative myeloid leukemia cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.266

Generation of antigen-presenting cells from tumor-infiltrated CD11b myeloid cells with DNA demethylating agent 5-aza-2'-deoxycytidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.266

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.266

Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.266

Chromatin maps, histone modifications and leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.266

Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.266

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.266

Histone deacetylases and epigenetic therapies of hematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.266

Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.266

Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.266

Current status of epigenetic treatment in myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.266

In vitro basis for treatment with hypomethylating agents and histone deacetylase inhibitors: can epigenetic changes be used to monitor treatment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.266

Hypomethylating agents in myelodysplastic syndromes changing the inevitable: the value of azacitidine as maintenance therapy, effects on transfusion and combination with other agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.266

Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.266

A role for nuclear phospholipase Cbeta 1 in cell cycle control

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.266

Nuclear PLCbeta1 is required for 3T3-L1 adipocyte differentiation and regulates expression of the cyclin D3-cdk4 complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.266

Cell cycle control genes and hematopoietic cell differentiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.266

A unique function for cyclin D3 in early B cell development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.266

Phosphoinositide-phospholipase C beta1 mono-allelic deletion is associated with myelodysplastic syndromes evolution into acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.266

Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.266

Proposals for the classification of the myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.266

The World Health Organization (WHO) classification of the myeloid neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.266

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.266

The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.266

The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNK-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.266

Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.266

Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.266

Histone deacetylase inhibitors: a new perspective for the treatment of leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.266

Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.266

Azacytidine plus verapamil induces the differentiation of a newly characterized biphenotypic human myeloid-B lymphoid leukemic cell line BW-90.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.266

Histone deacetylase is a target of valproic acid-mediated cellular differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.266

Downregulation of c-Myc is critical for valproic acid-induced growth arrest and myeloid differentiation of acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.266

Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.266

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.266

Epigenetic modifications in AML and MDS

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.266

inferred from DOI database lookup

7 January 2021

based on heuristic

Future directions in myelodysplastic syndrome: newer agents and the role of combination approaches

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.266

inferred from DOI database lookup

7 January 2021

based on heuristic

PI-PLCbeta-1 and activated Akt levels are linked to azacitidine responsiveness in high-risk myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.266

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/LEU.2010.266

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21109771%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference